Bayer: YAZ approved in Japan for the treatment of dysmenorrhea
Bayer Schering Pharma AG, Germany, and Bayer Yakuhin, Ltd., Japan, announced that the Japanese regulatory authorities have granted approval for YAZ® (3 mg drospirenone/20 mcg ethinyl estradiol) for the treatment of dysmenorrhea.
YAZ is available in the US, Europe, Latin America and the region Asia Pacific. In the US and several other countries in various regions, it is approved as an oral contraceptive as well as for the treatment of the symptoms of Premenstrual Dysphoric Disorder (PMDD) and/or moderate acne vulgaris in women desiring oral contraception.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Merck & Co. Announces New Name for its Animal Health Division
PolyTherics appoints new Chairman
Germany Begins its First AIDS Vaccine Trial, Partnering with IAVI
MedImmune to Collaborate With National Institutes of Health to Develop Pandemic Influenza Vaccine
Pharmexa presents data from influenza program
Dental_public_health
